Shattuck Labs (NASDAQ:STTK) Raised to Hold at Zacks Investment Research

Shattuck Labs (NASDAQ:STTK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company’s wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. “

Shares of NASDAQ STTK opened at $19.71 on Thursday. Shattuck Labs has a 12-month low of $17.15 and a 12-month high of $60.52. The stock has a market cap of $830.24 million and a PE ratio of -7.33. The company has a 50-day moving average of $20.05 and a 200 day moving average of $25.05.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Wednesday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.21). Shattuck Labs had a negative net margin of 453.65% and a negative return on equity of 28.65%. The business had revenue of ($4.23) million for the quarter. On average, research analysts anticipate that Shattuck Labs will post -1.76 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of STTK. Royal Bank of Canada boosted its holdings in Shattuck Labs by 170.1% in the 1st quarter. Royal Bank of Canada now owns 1,110 shares of the company’s stock valued at $32,000 after purchasing an additional 699 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Shattuck Labs by 90.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,086 shares of the company’s stock valued at $60,000 after purchasing an additional 988 shares during the last quarter. Legal & General Group Plc boosted its holdings in Shattuck Labs by 185.7% in the 2nd quarter. Legal & General Group Plc now owns 3,954 shares of the company’s stock valued at $115,000 after purchasing an additional 2,570 shares during the last quarter. SG Americas Securities LLC acquired a new position in Shattuck Labs in the 2nd quarter valued at about $126,000. Finally, ProShare Advisors LLC acquired a new position in Shattuck Labs in the 2nd quarter valued at about $200,000. Institutional investors own 61.21% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Recommended Story: Why does the United States have a lingering trade deficit?

Get a free copy of the Zacks research report on Shattuck Labs (STTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.